Balancing efficacy and safety of drugs is key for successful cancer therapy, as adverse
reactions can prohibit the use of efficacious treatments. Pralatrexate (PDX) is a novel …

It has been nearly 8 years since pralatrexate became the first drug approved by the US Food
and Drug Administration for the treatment of relapsed or refractory peripheral T-cell …

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity
Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma …

Abstract Abstract 2800 Background: Pralatrexate (FOLOTYN®) is an antifolate designed for
preferential tumor uptake and accumulation. Pralatrexate was granted accelerated approval …

T‐cell lymphomas (TCLs) are characterised by poor responses to therapy with brief
durations of remissions. An early phase study of pralatrexate has demonstrated dramatic …

Introduction: Peripheral T-cell lymphomas (PTCLs) are a group of rare malignancies
originating from clonal proliferation of mature, post-thymic T cells that represent 10–15% of …

BACKGROUND Pralatrexate (PDX) is an inhibitor of dihydrofolate reductase that was
rationally designed to improve cellular uptake and retention of the drug. Preclinical data …

Peripheral T-cell lymphomas (PTCL) represent about 12%–15% of non-Hodgkin lymphomas
and are characterized for being a molecularly heterogenous group of diseases. The optimal …

Introduction While patients with r/r TCL have a poor prognosis, significant progress has been
made over the past decade in developing new drugs and regimens for the disease. All of the …

In vitro treatment of human T-cell leukemia cells with 7-hydroxymethotrexate, the major
metabolite of methotrexate resulted in acquired resistance as a result of the complete loss of …